Table 4 Comparison the AD (mGy/MBq) of 177Lu-DOTA-IBA to other radiopharmaceuticals used for bone metastasis treatment
From: Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
Parameter | 177Lu-DOTA-IBA | 177Lu-DOTA-ZOL [33] | 89SrCl2 [37] | 153Sm-EDTMP [38] | 177Lu-EDTMP [38] | 188Re-HEDP [35] | 223RaCl2 |
|---|---|---|---|---|---|---|---|
Tumor lesion | 5.74 ± 1.73 | 4.21 ± 2.40 | 233 ± 166 | 6.22 ± 4.21 | 6.92 ± 3.92 | 3.83 ± 2.01 | 179.8(68–490) [36] |
Red marrow | 0.095 ± 0.02 | 0.36 ± 0.12 | 18.9 | 1.41 ± 0.6 | 0.83 ± 0.21 | 0.61 ± 0.21 | 73.9[34] |
Tumor–to–red marrow dose ratio | 60.42 | 13.9 | 12.3 | 4.4 | 8.31 | 6.28 | 2.4 |